Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01728259
Title First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Barbara Ann Karmanos Cancer Institute
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.